NADH Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: NADH evidence and protocol review

Longevity Research cofactor PowderCapsule verified

Also known as: Reduced NAD

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

100 mg, 500 mg

Storage

Follow the stabilized oral product label; reduced NADH is oxidation-sensitive, and generic RUO powder needs lot-specific stability documentation

Solubility

Water-soluble; sensitive to oxidation (must be stabilized formulation)

Catalog Description

NADH is the reduced form of NAD+, serving as the key electron donor in the mitochondrial electron transport chain for ATP production. Direct oral NADH supplementation faces bioavailability challenges (large, charged molecule), and clinical evidence is more limited than for upstream NAD+ precursors such as NMN and nicotinamide riboside, which are more extensively studied in recent human trials.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

No clinically established oral NADH half-life suitable for dosing; formulation stability and absorption vary

Onset

N/A - limited controlled human dosing data

Administration Routes (Research)

Oral in the cited human trials

Reported Research Effects

Electron transport chain / ATP production support (endogenous role)
Oral bioavailability limitations noted vs. NAD+ precursors

Reported Research Side Effects

No severe study-drug adverse effects in the small 10 mg crossover pilot
Combination-trial tolerability does not isolate NADH-specific effects
Product stabilization and oral formulation matter

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

10 mg stabilized oral NADH daily for 4 weeks, followed by a 4-week washout and crossover [Oral; Randomized double-blind crossover pilot in chronic fatigue syndrome; Daily]Source: PMID 10071523
20 mg NADH plus 200 mg coenzyme Q10 once daily for 8 weeks [Oral; Randomized double-blind combination trial in chronic fatigue syndrome; Daily]Source: PMID 25386668
20 mg NADH plus 200 mg coenzyme Q10 once daily for 12 weeks [Oral; Randomized double-blind combination trial in ME/CFS; Daily]Source: PMID 34444817

Research Notes

The 10 mg trial tested NADH alone; the 20 mg trials tested NADH only in combination with coenzyme Q10, so their outcomes cannot be attributed to NADH by itself.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

Stabilized oral NADH crossover pilot — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/10071523/

CoQ10 plus NADH randomized 8-week trial — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/25386668/

CoQ10 plus NADH randomized 12-week trial — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/34444817/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.